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Background:  This study was performed to determine the factors associated with long-term oral hypoglycemic agent (OHA) re-
sponsiveness in Korean type 2 diabetic patients.  
Methods:  Two groups of patients were selected among the type 2 diabetic patients who were followed for more than two years 
at a university hospital diabetes clinic. The OHA responsive group consisted of 197 patients whose HbA1c levels were maintained 
at ≤7% with OHA for more than two years. The OHA failure group consisted of 180 patients whose HbA1c levels were >8% in 
spite of optimal combined OHA therapy or patients who required insulin therapy within the two years of the study. 
Results:  The OHA failure group had higher baseline values of fasting and postprandial glucose, HbA1c, and lower fasting, post-
prandial, and delta C-peptide compared to those of the OHA responsive group. The OHA failure group also had a higher pro-
portion of female patients, longer diabetic duration, and more family history of diabetes. There were no significant differences in 
body mass index (BMI) or insulin resistance index between the two groups. Multiple logistic regression analysis showed that the 
highest quartile of baseline fasting, postprandial glucose, and HbA1c and the lowest quartile of postprandial and delta C-peptide 
were associated with an increased odds ratio of OHA failure after adjustment for age, sex, body mass index, and family history of 
diabetes. 
Conclusion:  Lower baseline values of postprandial and delta C-peptide and elevated fasting glucose and HbA1c are associated 
with long-term OHA responsiveness in Korean patients with type 2 diabetes mellitus.
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INTRODUCTION
Defective insulin secretion and insulin resistance are the two 
main factors causing the development and progression of type 
2 diabetes [1]. In the UK Prospective Diabetes Study [2], after 
an initial improvement, glycemic control continues to deterio-
rate despite the use of oral agents aimed to enhance insulin se-
cretion and to reduce insulin resistance. This deterioration can 
be attributed to the progressive decline of β-cell dysfunction, 
and insulin treatment is usually required in type 2 diabetic pa-
tients who are not able to obtain good glycemic control with 
an oral hypoglycemic agent. Although new treatment options 
for type 2 diabetic patients are increasingly available, agreement 
on the most effective treatment approach for individual patients 
has not been achieved. Prediction of poor response to an oral 
hypoglycemic agent may be helpful in achieving good glyce-
mic control through earlier administration of insulin therapy. 
  Although many previous studies have investigated the asso-
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ciation between markers of β-cell function and future insulin 
use, there is no reliable predictor of responsiveness to oral hy-
poglycemic agents in clinical practice [3]. Previous studies have 
reported that plasma glucose, HbA1c, and serum C-peptide 
are associated with insulin use [4-10]. Those studies focused 
on predicting future insulin use, but many type 2 diabetic pa-
tients who were categorized as non-insulin requiring were not 
adequately controlled despite the use of an oral hypoglycemic 
agent. In addition, most of the studies were cross-sectional or 
had short durations of follow-up and included small numbers 
of participants. To identify the factors associated with oral hy-
poglycemic agent responsiveness, we comprehensively exam-
ined the association between various clinical factors and oral 
hypoglycemic agent failure in Korean patients with type 2 dia-
betes mellitus.
METHODS
Participants
Data for Korean patients with type 2 diabetes mellitus who 
visited the diabetes clinic at Soonchunhyang University Bu-
cheon Hospital during 2001 to 2007 were analyzed. Individu-
als diagnosed with type 1 diabetes mellitus (fasting serum C-
peptide <0.6 ng/mL and postprandial serum C-peptide <1.0 
ng/mL or history of diabetic ketoacidosis), with renal insuffi-
ciency (serum Cr >1.3 mg/dL), alcoholism, chronic liver dis-
ease, chronic infection, endocrine disorders (e.g., thyroid dys-
function, pituitary disease, adrenal disease, or receiving hor-
mone replacement therapy) or malignancy were excluded. In-
dividuals who had been taking drugs that could influence glu-
cose metabolism were also excluded, as were individuals who 
had been treated with insulin before participation in the study 
or whose follow-up duration was shorter than two years. In the 
remaining 1,060 type 2 diabetic patients, fasting and postpran-
dial serum C-peptide levels were measured at baseline, and 
the evaluation of glycemic control (fasting and postprandial 
glucose and HbA1c) was performed at baseline and during 
regular follow-up visits. These follow-up visits occurred at two- 
to four-month intervals and were conducted by endocrinology 
specialists, who adjusted anti-diabetic medications as needed 
to achieve HbA1c <6.5-7%. For the analyses, two groups of 
patients were selected from the 1,060 patients: the oral hypo-
glycemic agent (OHA) responsive group consisted of 197 pa-
tients whose HbA1c levels were controlled below 7% for more 
than two years with insulin secretagogues at a less than half 
maximum dose and/or other oral hypoglycemic agents (bigu-
anide, thiazolidinediones, α-glucosidase inhibitor, or DPP-4 
inhibitor). The OHA failure group consisted of 180 patients 
with the following conditions: 46 patients whose HbA1c levels 
were greater than 8% despite taking insulin secretagogues at 
more than the half maximum dose, in addition to other OHAs 
(biguanide, thiazolidinediones, alpha-glucosidase inhibitor, or 
DPP-4 inhibitor), and 134 patients who required insulin ther-
apy for glycemic control within two years. A total of 683 pa-
tients with the following conditions were excluded: patients 
who were not followed-up regularly, whose diabetes was con-
trolled with diet only, whose HbA1c levels were between 7% 
to 8%, who had taken an insufficient dose of OHA despite 
HbA1c levels greater than 8%, or whose HbA1c levels were 
controlled below 7% only after administration of the maxi-
mum dose of insulin secretagogues. This study was approved 
by the Institutional Review Board of Soonchunhyang Univer-
sity Bucheon Hospital.
Measurements
Fasting and postprandial 2-hour glucose and C-peptide levels, 
glycated hemoglobin (HbA1c), serum total cholesterol, tri-
glyceride, high density lipoprotein cholesterol, low density li-
poprotein cholesterol, and creatinine were determined at base-
line. HbA1c was measured using ion-exchange HPLC (Bio-
Rad, Hercules, CA, USA), and serum C-peptide was deter-
mined using an immunoradiometric assay (Immunotech, 
Prague, Czech Republic). Delta C-peptide was defined as the 
difference between postprandial serum C-peptide and fasting 
C-peptide level. The homeostasis model assessment index for 
insulin resistance (HOMA-IR) was calculated with the formu-
la: HOMA-IR=fasting plasma insulin (μU/mL)×fasting plas-
ma glucose (mmol/L)/22.5. 
Statistical analysis
Data are presented as the mean±standard deviation. Statisti-
cal analysis was performed using SPSS version 14.0 for Win-
dows
® (SPSS Inc., Chicago, IL, USA). Variables that were not 
distributed normally, such as blood concentrations of glucose, 
triglycerides, and C-peptide level, were log-transformed be-
fore analysis. The unpaired Student’s t-test was used to com-
pare differences between the two groups, and the χ
2 test was 
used to compare percentages. Multivariate logistic regression 
analyses were used to estimate the odds ratios (ORs) for OHA 
failure after adjusting for other clinical and biochemical vari-284
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ables. The receiver operating characteristic (ROC) curves were 
used to determine the predictive abilities of variables for OHA 
failure. A P value of less than 0.05 was considered statistically 
significant.
RESULTS
In the OHA responsive group, sulfonylurea was used in 64% 
of the patients, metformin in 86%, thiazolidinediones in 30%, 
α-glucosidase inhibitor in 10%, and DPP-4 inhibitor in 5%. In 
the OHA failure group, sulfonylurea was used in all of the pa-
tients, metformin in 73%, thiazolidinediones in 28%, α-
glucosidase inhibitor in 6%, and DPP-4 inhibitor in 5%. The 
baseline characteristics of the study participants are shown in 
Table 1. Patients in the OHA failure group showed higher 
baseline values of HbA1c, fasting and postprandial plasma 
glucose, and lower values of fasting, postprandial, and delta C-
peptide levels compared to those of patients in the OHA re-
sponsive group. Also, patients in the OHA failure group had a 
significantly higher proportion of women, more family history 
of diabetes, and longer duration of diabetes. When the patients 
were divided into three groups according to diabetic duration, 
patients with shorter diabetic duration showed a lower rate of 
OHA failure compared to those of patients with longer diabet-
ic duration (<5 years, 33.5%; 5 to 10 years, 63.4%; >10 years, 
81.5%; P<0.001). The proportion of drug-naive patients was 
higher in the OHA responsive group compared to that in the 
OHA failure group (29.9% vs. 5.6%, P<0.001). There was no 
significant difference between the two groups regarding the 
prevalence of hypertension, body mass index, or HOMA-IR. 
  To identify independent factors that are associated with poor 
response to oral hypoglycemic agent, we performed multiple 
logistic regression analysis after categorizing HbA1c, fasting 
and postprandial plasma glucose, fasting and postprandial se-
Table 1. Clinical characteristics of the patients at baseline
Characteristic OHA responsive group OHA failure group P value
No. (%) 197 (18.6) 180 (17.0)
Male/Female 122/75 (61.9/38.1) 85/95 (47.2/52.8) 0.003
Age, yr 58.2±11.2 (22-89) 57.1±12.0 (38-81) 0.347
Duration of DM, yr 4.1±5.0 (0-35) 8.6±6.4 (0-31) <0.001
Family history of DM 45 (23.0)  61 (33.9) 0.013
Hypertension 121 (65.8) 111 (65.3) 0.508
BMI, kg/m
2 25.2±3.6 25.1±4.0 0.654
HbA1c, % 7.9±1.8 (4.0-16.2) 9.0±1.8 (4.8-12.6) <0.001
Fasting plasma glucose, mg/dL 151±55 (63-327) 181±64 (70-353) <0.001
Postprandial plasma glucose, mg/dL 236±90 (117-423) 271±93 (120-437) 0.001
Fasting serum C-peptide, ng/mL 2.9±1.7 (0.6-12.3)  2.5±1.3 (0.7-8.5) 0.005
Postprandial serum C-peptide, ng/mL 7.7±3.8 (2.0-18.9) 5.6±2.9 (1.3-13.5) <0.001
SBP, mm Hg 133±16 131±21 0.418
DBP, mm Hg 79±11 79±13 0.943
Total cholesterol, mg/dL 195±22 (79-396) 200±44 (115-282) 0.291
LDL-C, mg/dL 119±40 (35-294) 114±40 (52-200) 0.554
HDL-C, mg/dL 44±11 (19-78) 44±11 (32-75) 0.917
Triglycerides, mg/dL 191±134 (42-906) 189±128 (52-642) 0.875
Delta C-peptide, ng/mL 4.7±4.0 (0.1-15.9) 3.2±2.4 (0.1-9.3) <0.001
HOMA-IR 1.07±1.14 (0.06-7.92) 1.49±2.77 (0.10-33.16) 0.060
Data are presented as mean±standard deviation (range) or number (%).
P values were determined using the unpaired t-test or χ
2 test.
DM, diabetes mellitus; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure, LDL-C, low density lipoprotein cho-
lesterol; HDL-C, high density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment index for insulin resistance.285
Oral hypoglycemic agent responsiveness in type 2 diabetes
Diabetes Metab J 2011;35:282-289 http://e-dmj.org
rum C-peptide, and delta C-peptide into quartiles (Table 2). 
In the unadjusted model, the highest quartiles of HbA1c and 
plasma glucose, and lowest quartile of C-peptide were associ-
ated with increased risk of oral hypoglycemic agent failure. We 
adjusted for potential confounding factors which were signifi-
cantly different between the two groups (sex, family history of 
diabetes) or that had been reported to be associated with OHA 
failure in previous studies (age, BMI). Adjustment for age, sex, 
BMI, and familial history of diabetes attenuated, but did not 
eliminate associated risks except in the case of fasting C-pep-
tide quartile. Postprandial and delta C-peptide quartiles were 
more significantly associated with oral hypoglycemic agent 
failure than was fasting serum C-peptide quartile. 
  Receiver operating characteristic curve (Fig. 1) analyses 
showed that the area under the curve (AUC) for HbA1c, fast-
ing glucose, postprandial glucose, fasting C-peptide, postpran-
dial C-peptide, and delta C-peptide were 0.667, 0.660, 0.596, 
0.587, 0.667, and 0.665, respectively. Based on these AUCs, the 
predictive abilities of HbA1c, fasting glucose, postprandial C-
peptide, and delta C-peptide for OHA failure were similar, but 
slightly higher than those of postprandial glucose and fasting 
C-peptide. Diagnostic performances, including the sensitivity 
and specificity, were substantially dependent on the chosen 
cutoff values (Table 3). The cutoff points showing maximum 
sensitivity plus specificity were baseline HbA1c 8.5%, fasting 
glucose 160 mg/dL, postprandial C-peptide 6.5 ng/mL, and 
delta C-peptide 4.0 ng/mL, which resulted in sensitivity and 
specificity of around 60% to 70%. 
Table 2. Medians (range) of quartiles and OR (95% CI) for oral hypoglycemic agent failure in Korean type 2 diabetic patients
Variable Quartile 1 Quartile 2 Quartile 3 Quartile 4 P for trend
 a
HbA1c
Median (range), % 6.2 (3.1-6.9) 7.7 (7.0-8.3) 9.0 (8.4-9.5) 10.9 (9.6-16.2)
Unadjusted OR 1 1.196 (0.547-2.616) 2.485 (1.228-5.027) 5.038 (2.546-9.970) <0.001
Adjusted OR
 a 1 1.604 (0.659-3.906) 4.170 (1.827-9.520) 6.885 (3.088-13.230) <0.001
Fasting plasma glucose
Median (range), mg/dL 104 (67-121) 135 (122-149) 173 (150-194) 247 (195-555)
Unadjusted OR 1 1.429 (0.726-2.814) 2.075 (1.078-3.993) 3.879 (2.107-7.140) <0.001
Adjusted OR
 a 1 1.803 (0.854-3.811) 2.484 (1.190-5.185) 5.289 (2.635-10.617) <0.001
Postprandial plasma glucose
Median (range), mg/dL 139 (71-179) 219 (180-245) 277 (246-308) 379 (309-548)
Unadjusted OR 1 2.279 (1.116-4.655) 2.030 (1.028-4.005) 3.861 (2.018-7.386) 0.001
Adjusted OR
 a 1 2.693 (1.228-5.906) 2.198 (1.054-4.586) 4.349 (2.121-8.914) 0.001
Fasting serum C-peptide
Median (range), ng/mL 1.36 (0.62-1.75) 2.08 (1.76-2.39) 2.80 (2.40-3.25) 4.57 (3.26-14.30)
Unadjusted OR 2.003 (1.160-3.458) 1.900 (1.036-3.487) 1.286 (0.720-2.296) 1 0.050
Adjusted OR
 a 1.494 (0.784-2.845) 1.752 (0.886-23.465) 1.081 (0.570-12.051) 1 0.337
Postprandial serum C-peptide
Median (range), ng/mL 2.96 (1.37-4.10) 4.97 (4.13-5.99) 7.21 (6.02-8.87) 11.67 (8.88-18.90)
Unadjusted OR 3.514 (1.844-6.697) 2.727 (1.398-5.321) 1.147 (0.558-2.361) 1 <0.001
Adjusted OR
 a 2.776 (1.359-5.669) 1.819 (0.883-3.747) 0.991 (0.461-2.131) 1 0.008
Delta C-peptide
Median (range), ng/mL 1.15 (0.10-1.90) 2.62 (1.93-3.27) 4.37 (3.29-5.59) 8.25 (5.67-15.93)
Unadjusted OR 4.099 (2.090-8.042) 1.641 (0.883-3.051) 1.247 (0.650-2.392) 1 <0.001
Adjusted OR
 a 3.205 (1.551-6.623) 1.187 (0.603-2.337) 0.935 (0.463-1.884) 1 0.003
OR, odds ratio; CI, confidence interval.
aAdjusted for sex, age, BMI, and family history of diabetes mellitus. 286
Kim B-Y, et al.
Diabetes Metab J 2011;35:282-289 http://e-dmj.org
DISCUSSION
In the present study conducted in Korean type 2 diabetic pa-
tients, we confirmed that lower serum C-peptide and elevated 
plasma glucose and HbA1c at baseline were associated with 
long-term OHA failure. These associations were independent 
of confounding factors, such as age, sex, and BMI. Female sex, 
longer duration of diabetes, and familial history of diabetes were 
also associated with OHA failure. In contrast, there was no as-
sociation between BMI and OHA responsiveness. 
  It has been established that severe degree of hyperglycemia 
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Fig. 1. Receiver operating characteristic curves for the predic-
tion of oral hypoglycemic agent failure in Korean type 2 dia-
betic patients. (A) HbA1c, fasting and postprandial plasma 
glucose. (B) Fasting, postprandial, and delta C-peptides.
Table 3. Area under the receiver operating characteristic 
curves (AUCs), sensitivity, and specificity using various cutoff 
points for oral hypoglycemic agent failure 
Variable AUC
Sensitiv-
ity, % 
Specific-
ity, %
HbA1c, % 0.667
≥7.0 87.1 33.7
≥7.5 81.0 42.9
≥8.0 70.7 54.0
≥8.5 61.2 66.3
≥9.0 50.3 72.4
Fasting plasma glucose, mg/dL 0.660
≥120 85.0 31.3
≥140 70.7 51.5
≥160 57.8 66.3
≥180 45.6 76.7
≥200 34.0 84.7
Postprandial plasma glucose, mg/dL 0.596
≥200 72.1 35.0
≥220 68.0 42.3
≥240 56.5 52.1
≥260 47.6 62.6
≥280 42.9 71.8
Fasting serum C-peptide, ng/mL 0.587
≤1.50 26.2 85.1
≤2.00 38.0 75.5
≤2.50 50.0 61.5
≤3.00 65.5 44.4
≤3.50 88.3 24.7
Postprandial serum C-peptide, ng/mL 0.667
≤5.00 48.1 75.4
≤5.50 58.2 72.1
≤6.00 61.5 62.9
≤6.50 67.1 58.0
≤7.00 73.1 50.0
Delta C-peptide, ng/mL 0.665
≤2.50 46.8 76.6
≤3.00 50.5 71.0
≤3.50 55.3 63.7
≤4.00 67.7 58.2
≤4.50 77.9 47.1287
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cross-sectional analyses including only small numbers of pa-
tients, and no study comprehensively examined the associa-
tions between various clinical variables with long-term predic-
tors of OHA failure. In addition, in most previous studies per-
formed in the 1980s and 1990s, the target values for glycemic 
control were much higher than the current guideline. There-
fore, the ‘good control’ in previous studies was inadequate in 
light of current recommendations. The current study had the 
strength that it included a relatively large number of Korean 
type 2 diabetic patients, used strict criteria for OHA respon-
siveness, and utilized regular follow-up data covering more 
than two years in all patients.
  Female sex, longer duration of diabetes mellitus, and famil-
ial history of diabetes mellitus were also found to be associated 
with OHA failure. In contrast, there was no association between 
BMI and OHA responsiveness. A recent study in Japanese 
type 2 diabetic patients showed that lower BMI had a strong 
predictive ability for future insulin use, similar to fasting plas-
ma glucose, serum and urine C-peptide levels [11]. The exact 
reason for these inter-study discrepancies is not clear at pres-
ent, but there were several differences in study design and pa-
tient characteristics between studies. While our study patients 
were mostly managed in an outpatient clinic, the patients in 
the Japanese study were those who had admitted for glycemic 
control. Therefore, their participants generally had poorer gly-
cemic control and longer duration of diabetes compared with 
those of our study participants. It is also possible that abnor-
malities in body fat distribution are more important than BMI. 
  Little is known about the associations between female sex, 
family history of diabetes mellitus and OHA failure. There 
were no significant differences in fasting and postprandial C-
peptide levels between male/female groups or positive/nega-
tive family history groups. To better understand these results, 
further studies are needed.
  Our study has several limitations that must be taken into 
account. First, since this study was a cross-sectional analysis, 
prospective controlled studies are needed to confirm the use-
fulness of C-peptide in predicting long-term OHA responsive-
ness in type 2 diabetes patients. Second, our study population 
was a cohort of patients cared for in a single center; therefore, 
our results may not be generalized to the whole Korean type 2 
diabetic patients. However, the majority of our study partici-
pants were typical type 2 diabetic patients commonly encoun-
tered at outpatient-based diabetes clinics in real practice. Third, 
we used only fasting and postprandial C-peptide levels as a 
and low endogenous insulin secretion are associated with in-
sulin use in type 2 diabetic patients [4,5,7,9,11]. Therefore, it is 
not surprising that elevated plasma glucose and HbA1c, and 
low C-peptide quartile at baseline were associated with OHA 
failure in this study. Among the glycemic variables, fasting 
glucose and HbA1c had better discriminative ability than did 
postprandial glucose level. This may be due to greater variabil-
ity of postprandial glucose level, which is greatly influenced by 
dietary factors. In contrast, among the C-peptide measures, 
postprandial or delta C-peptide levels were better markers of 
OHA failure than was fasting serum C-peptide. This is consis-
tent with previous studies in Korean type 2 diabetic patients 
that showed postprandial or delta C-peptide levels are more 
closely correlated with OHA responsiveness than is fasting C-
peptide [12-14]. This reflects the fact that a β-cell’s capacity to 
respond to stimulation is more important than basal insulin 
secretion in determining response to oral hypoglycemic agents. 
A Japanese study [9] has reported that the serum and urinary 
C-peptide levels corrected for the fasting plasma glucose were 
useful for decision making regarding insulin therapy in patients 
with type 2 diabetes. In the present study, however, correction 
for fasting plasma glucose level did not improve the predictive 
power of fasting C-peptide (data not shown). 
  Our results suggest that impaired β-cell function may be a 
cause of poor response to OHA. However, reverse causation is 
also a potential explanation. Unger and Grundy [15] introduced 
the concept of glucotoxicity, that continuous over-stimulation 
of β-cells by glucose could lead to depletion of insulin stores, 
worsening of hyperglycemia, and finally deterioration of β-cell 
function. Further prospective studies are needed to clarify 
whether β-cell dysfunction or hyperglycemia is the primary 
defect.
  Madsbad et al. [16] reported that patients with a post-stim-
ulatory C-peptide level greater than 1.80 ng/mL appeared to 
be non-insulin dependent. In our analysis, the postprandial C-
peptide cutoff value (5.5 to 6.5 ng/mL) was that for good gly-
cemic control with OHA, not for insulin-independence for 
prevention of life-threatening acute metabolic complications. 
Therefore, it is natural that much higher insulin secretory ca-
pacity is required for good glycemic control compared to that 
needed for minimal insulin independence for life. Previous 
studies in Koreans have also reported that postprandial serum 
C-peptide or glucagon-stimulated serum C-peptide responses 
are useful indicators of insulin requirement in type 2 diabetic 
patients [12,13,17-19]. However, most of the studies were 288
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measure of β-cell function. However, it is not practical to per-
form intravenous glucose tolerance test or hyperglycemic clamp 
study in clinical settings, and it has been shown that fasting 
and postprandial C-peptide levels are well-correlated with glu-
cagon-stimulated or 24-hour urine C-peptide [11,13,19,20]. 
  Despite these limitations, we provided evidence that lower 
baseline values of postprandial and delta C-peptide, and ele-
vated fasting glucose and HbA1c are useful factors that are as-
sociated with OHA failure in Korean patients with type 2 dia-
betes mellitus. Further large prospective studies are required 
to confirm the clinical usefulness of those clinical variables in 
predicting the responsiveness to an oral hypoglycemic agent 
and in clinical decision making for the choice of therapy in 
type 2 diabetic patients.
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